.Pharmacolibrary.Drugs.ATC.J.J05AX27 .Pharmacolibrary.Drugs.ATC.J.J05AX27| name: | Favipiravir |
| ATC code: | J05AX27 | route: | oral |
| n-compartments | 1 |
Favipiravir is an antiviral drug developed for the treatment of influenza and has been investigated for off-label use in treating other viral infections, including COVID-19. It inhibits the RNA-dependent RNA polymerase of RNA viruses. It is approved for influenza treatment in Japan but not widely approved elsewhere.
Pharmacokinetic parameters in healthy adult subjects after oral administration.
Siripongboonsitti, T, et al., & Mahanonda, N (2023). Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers. Clinical pharmacology in drug development 12(1) 14–20. DOI:10.1002/cpdd.1149 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35877195
Sürmelioğlu, N, et al., & Allegaert, K (2024). Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned. International journal of clinical pharmacology and therapeutics 62(8) 345–352. DOI:10.5414/CP204496 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38920081